Zogenix’s Fintepla Reduces Drop Seizure Rates, But Is It Enough?
Executive Summary
Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not be as good as seen with GW Pharma’s Epidiolex.
You may also be interested in...
Keeping Track: Intercept Submits OCA For NASH; Zogenix’ Fintepla Returns; US FDA Approves Bavarian Nordic Vaccine
The latest drug development news and highlights from our US FDA Performance Tracker
US FDA Filing Mistake For Fintepla Dents Zogenix
Zogenix seems only to have itself to blame for an unexpected refusal to file letter from the US agency for its novel treatment for Dravet syndrome that sent its shares tumbling by 31% on NASDAQ in after-hours trading.
GW's Epidiolex Epilepsy Data Paves Way For Cannabinoids
Safety and efficacy in study published in New England Journal of Medicine bode well for cannabinoid therapy Epidiolex, which is headed to FDA mid-year.